文献速递创伤与烧伤呼吸衰竭与机械通气重症综合管理与镇静镇痛

低分子肝素与普通肝素预防严重创伤后肺栓塞的有效性:倾向匹配分析

Effectiveness of low-molecular-weight heparin versus unfractionated heparin to prevent pulmonary embolism following major trauma: A propensity-matched analysis.
PubMed 文献 · J Trauma Acute Care Surg · 2017-01-01
一句话结论严重创伤患者使用低分子肝素(vs 普通肝素)进行血栓预防与肺栓塞风险显著降低相关(OR 0.56;95%CI 0.50-0.63),作者认为低分子肝素应作为预防肺栓塞的首选抗凝药。

本研究基于美国外科医师学会创伤质量改进项目(2012-2015)数据,纳入接受低分子肝素或普通肝素血栓预防的严重创伤成人患者,排除5天内死亡或出院者。共纳入217家创伤中心153,474例患者,低分子肝素使用率74%,肺栓塞发生率1.8%。倾向评分匹配后得到75,920例平衡队列,低分子肝素组肺栓塞发生率1.4% vs 普通肝素组2.4%(OR 0.56;95%CI 0.50-0.63),各损伤亚组结果一致。低分子肝素使用率最高四分位中心(中位使用率95%)肺栓塞发生率1.2% vs 最低四分位中心(中位使用率39%)2.0%(OR 0.59;95%CI 0.48-0.74)。作者结论认为低分子肝素应作为严重创伤患者预防肺栓塞的首选抗凝药。

要点

  • 倾向匹配队列75,920例中,低分子肝素组肺栓塞发生率1.4% vs 普通肝素组2.4%,OR 0.56(95%CI 0.50-0.63)。
  • 低分子肝素使用率最高四分位中心(中位95%)肺栓塞1.2% vs 最低四分位中心(中位39%)2.0%,OR 0.59(95%CI 0.48-0.74)。
  • 亚组分析包括钝性多系统损伤、穿透性躯干损伤、休克、重型颅脑损伤和孤立骨科损伤,结果一致。
  • 研究排除5天内死亡或出院的患者,纳入者为严重创伤成人且接受低分子肝素或普通肝素血栓预防。
  • 作者结论认为低分子肝素应作为严重创伤患者预防肺栓塞的首选抗凝药。

适用人群与场景

  • 美国外科医师学会创伤质量改进项目(2012-2015)中接受低分子肝素或普通肝素血栓预防的严重创伤成人患者。
  • 排除5天内死亡或出院的患者。
  • 亚组包括钝性多系统损伤、穿透性躯干损伤、休克、重型颅脑损伤和孤立骨科损伤患者。

研究设计与关键结果

  • 研究类型:基于美国外科医师学会创伤质量改进项目(2012-2015)的倾向匹配分析,纳入217家创伤中心153,474例接受低分子肝素或普通肝素血栓预防的严重创伤成人患者。
  • 低分子肝素使用率74%,总体肺栓塞发生率1.8%。
  • 倾向评分匹配后队列75,920例,低分子肝素组肺栓塞1.4% vs 普通肝素组2.4%,OR 0.56(95%CI 0.50-0.63)。
  • 亚组分析(钝性多系统损伤、穿透性躯干损伤、休克、重型颅脑损伤、孤立骨科损伤)结果一致。
  • 低分子肝素使用率最高四分位中心(中位使用率95%)肺栓塞1.2% vs 最低四分位中心(中位使用率39%)2.0%,OR 0.59(95%CI 0.48-0.74)。

证据类型、等级与局限

  • 证据类型:治疗性研究,证据等级 level III。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为低分子肝素应作为严重创伤患者预防肺栓塞的首选抗凝药。
  • 低分子肝素使用率较高的创伤中心报告的肺栓塞发生率较低。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Pulmonary embolism (PE) is a leading cause of delayed mortality in patients with severe injury. While low-molecular-weight heparin (LMWH) is often favored over unfractionated heparin (UH) for thromboprophylaxis, evidence is lacking to demonstrate an effect on the occurrence of PE. This study compared the effectiveness of LMWH versus UH to prevent PE in patients following major trauma.

METHODS: Data for adults with severe injury who received thromboprophylaxis with LMWH or UH were derived from the American College of Surgeons Trauma Quality Improvement Program (2012-2015). Patients who died or were discharged within 5 days were excluded. Rates of PE were compared between propensity-matched LMWH and UH groups. Subgroup analyses included patients with blunt multisystem injury, penetrating truncal injury, shock, severe traumatic brain injury, and isolated orthopedic injury. A center-level analysis was performed to determine if practices with respect to choice of prophylaxis type influence hospital PE rates.

RESULTS: We identified 153,474 patients at 217 trauma centers who received thromboprophylaxis with LMWH or UH. Low-molecular-weight heparin was given in 74% of patients. Pulmonary embolism occurred in 1.8%. Propensity score matching yielded a well-balanced cohort of 75,920 patients. After matching, LMWH was associated with a significantly lower rate of PE compared with UH (1.4% vs. 2.4%; odds ratio, 0.56; 95% confidence interval, 0.50-0.63). This finding was consistent across injury subgroups. Trauma centers in the highest quartile of LMWH utilization (median LMWH use, 95%) reported significantly fewer PE compared with centers in the lowest quartile (median LMWH use, 39%; 1.2% vs. 2.0%; odds ratio, 0.59; 95% confidence interval, 0.48-0.74).

CONCLUSIONS: Thromboprophylaxis with LMWH (vs. UH) was associated with significantly lower risk of PE. Trauma centers favoring LMWH-based prophylaxis strategies reported lower rates of PE. Low-molecular-weight heparin should be the anticoagulant agent of choice for prevention of PE in patients with major trauma.

LEVEL OF EVIDENCE: Therapeutic study, level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Byrne JP, Geerts W, Mason SA, et al. Effectiveness of low-molecular-weight heparin versus unfractionated heparin to prevent pulmonary embolism following major trauma: A propensity-matched analysis. J Trauma Acute Care Surg. 2017. PMID: 27906870. doi:10.1097/TA.0000000000001321

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。